PD0053
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, 18-MONTH PHASE 2A STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORAL UCB0599 IN STUDY PARTICIPANTS WITH EARLY PARKINSON’S DISEASE
- Sex at Birth: Any
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase II
- Conditions Being Studied: Parkinsons Disease
Study Purpose
This Phase II study will help to determine if UCB0599, an alpha-synuclein aggregation inhibitor, will slow progression (worsening) of early Parkinson's disease compared to placebo. Volunteers must be within 2 years of PD diagnosis and not on medication for their PD.
Locations
UH Suburban Health Center
1611 South Green Road
South Euclid OH, 44121
UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106
UH Westlake Health Center
960 Clague Road
Westlake OH, 44145
- UH IRB: SITE00001762
- StudyID: 2022-0965
- ClinicalTrials.gov: NCT04658186
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422